Trial Profile
A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors NeuroDerm
- 12 Apr 2024 According to a Mitsubishi Tanabe Pharma Corporation Media Release, data from the study will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
- 28 Aug 2023 According to a Mitsubishi Tanabe Pharma America Media release, results from this study will be shared at the International Congress of Parkinson's Disease and Movement Disorder Society (MDS), being held in Copenhagen, Denmark, August 27-31.
- 01 May 2020 Results of secondary analysis evaluating the efficacy of two ND0612 dosing regimens (R1: 24 hours infusion and R2: 14 hours daytime infusion) on patient-rated activities of daily living and quality of life were presented at the 72nd Annual Meeting of the American Academy of Neurology